SUGEN, Inc. is a biopharmaceutical company focusing on the development of new classes of small molecule drugs which interact in a specific manner with different members of the tyrosine kinase, serine-threonine kinase and tyrosine phosphatase families of signal transduction molecules, and their signalling pathways. These pathways are involved in a number of human diseases including cancer and diabetes, as well as disorders of the body's immune defenses and neurological systems. The Company has research and development collaborations with Zeneca, ASTA Medica and Allergan.